Program
SHR-1905
A development code. Also written as “SHR-1905 Injection”.
In Jiangsu HengRui Medicine's pipeline, TSLP
. Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Jul 25, 20257 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 73 open or running | phase 3since Jul 25, 2025 | Mar 11, 2021 | Jan 2028phase 3 · NCT07098403 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-1905
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2021First study: phase 1 study in AsthmaFirst studyNCT04800263 · 50 enrolled · Australia
- Oct 14, 2022Phase 2 study in AsthmaNCT05593250 · 260 enrolled · China
- May 25, 2023Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT05891483 · 114 enrolled · China
- Jan 9, 2025Phase 2 study in Adolescent AsthmaNCT06786455 · 9 enrolled · China
- Jul 25, 2025Phase 3 study in AsthmaNCT07098403 · 408 planned · China
- Aug 13, 2025Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07132827 · 280 planned · China
- Sep 30, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07211542 · 75 planned · China
Ahead
- Jan 2028Primary completion: phase 3 study in AsthmaNCT07098403
- Apr 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07132827
TargetBeta
“TSLP”the company's pipeline, read by Claude · source
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tezepelumabrule | AstraZeneca | phase 4 | 34 |
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| TQC2731 | Sino Biopharmaceutical | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07211542Moderate-to-severe Atopic Dermatitis · China | 2 | Recruiting | Sep 2026 | 75 |
| NCT07132827Chronic Rhinosinusitis With Nasal Polyps · China | 3 | Recruiting | Apr 2028 | 280 |
| NCT07098403Asthma · China | 3 | Recruiting | Jan 2028 | 408 |
| NCT06786455Adolescent Asthma · China | 2 | Completed | Dec 3, 2025 | 9 |
| NCT05891483Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Jan 21, 2026 | 114 |
| NCT05593250Asthma · China | 2 | Completed | Dec 5, 2025 | 260 |
| NCT04800263Asthma · Australia | 1 | Completed | Nov 12, 2022 | 50 |
How it is read
Names in the registry
- “SHR-1905 Injection”, 5 entries
- “SHR-1905”, 2 entries
Codes read as this program: SHR1905.
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Nasal Polyps, 2 studies
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.